Exact Therapeutics AS (FRA:56F) Other Stockholders Equity: €0.01 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:56F Exact Therapeutics AS FRA:56F
21 GF Score
Price €0.03
! 2 Warning Signs
View Full Analysis

What is Exact Therapeutics AS Other Stockholders Equity?

Exact Therapeutics AS FRA:56F +2.00% 21 Other Stockholders Equity is €0.01 Mil as of Dec. 2025. GuruFocus rates FRA:56F with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Exact Therapeutics AS's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €0.01 Mil.

Exact Therapeutics AS's quarterly Other Stockholders Equity declined from Dec. 2024 (€0.02 Mil) to Jun. 2025 (€0.02 Mil) and declined from Jun. 2025 (€0.02 Mil) to Dec. 2025 (€0.01 Mil).

Exact Therapeutics AS's annual Other Stockholders Equity increased from Dec. 2023 (€-0.00 Mil) to Dec. 2024 (€0.02 Mil) but then declined from Dec. 2024 (€0.02 Mil) to Dec. 2025 (€0.01 Mil).

Exact Therapeutics AS Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Exact Therapeutics AS's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exact Therapeutics AS Other Stockholders Equity Chart

Exact Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only -0.00 0.00 -0.00 0.02 0.01

Exact Therapeutics AS Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.02 0.02 0.01
FRA:56F
21GF Score
Exact Therapeutics AS FRA:56F
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exact Therapeutics AS Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0.01 Mil mean?
Exact Therapeutics AS (FRA:56F) has a Other Stockholders Equity of €0.01 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Exact Therapeutics AS and its competitors.
Is Exact Therapeutics AS's Other Stockholders Equity too high?
Exact Therapeutics AS's current Other Stockholders Equity is €0.01 Mil. Overall, Exact Therapeutics AS has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Exact Therapeutics AS's Other Stockholders Equity compare to VRTX and REGN?
Exact Therapeutics AS's Other Stockholders Equity of €0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Exact Therapeutics AS and its competitors. Exact Therapeutics AS's current Other Stockholders Equity is €0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exact Therapeutics AS stock overvalued right now?
Exact Therapeutics AS (FRA:56F) has a current Other Stockholders Equity of €0.01 Mil. The current Other Stockholders Equity is €0.01 Mil. Exact Therapeutics AS's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Exact Therapeutics AS (FRA:56F), the current Other Stockholders Equity is €0.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exact Therapeutics AS Business Description

Other Exchanges EXTX:Norway
Address Ostre Aker Vei 19, Oslo, NOR, 0581
Exact Therapeutics AS is a clinical-stage biotechnology company focused on developing Acoustic Cluster Therapy (ACT), a non-invasive ultrasound-mediated technology for targeted enhancement of therapeutic agents. Its ACT platform (PS101) is being evaluated mainly in oncology, including pancreatic cancer and liver metastases, with additional applications in immuno-oncology, gene therapy, and central nervous system disorders.
21GF Score

Get the complete analysis for FRA:56F

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price